Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
69 participants
INTERVENTIONAL
2011-01-31
2014-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Outcome measures will be social anxiety symptoms and severity as measured by gold standard questionnaires as well as diagnosis of social anxiety disorder derived from structured clinical interviews based on Diagnostic and Statistical Manual (DSM) IV criteria.
The investigators expect to find significant reduction in social anxiety symptoms in all of the groups, with the cognitive behavior therapy group showing greater reduction in symptoms than the other groups. Mechanisms of change in all of the groups will be examined via measures of cognitive biases, affect, and other common and specific factors.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Attention Bias Modification Treatment (ABMT) and Cognitive-Behavioral Group Therapy (CBGT) in Social Anxiety Disorder
NCT02338453
Attention Bias Modification Training for Social Phobia (ABMSP)
NCT06054386
Augmenting Effects of ABMT on CBT in Anxious Children: A Randomized Clinical Trial
NCT01730625
Attention Bias Modification Versus Attention Control in Treatment of Social Anxiety
NCT05018260
Attention Bias Modification Treatment (ABMT) for Patients With Post Traumatic Stress Disorder (PTSD)
NCT01368302
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Outcome measures will be social anxiety symptoms and severity as measured by gold standard questionnaires as well as diagnosis of social anxiety disorder derived from structured clinical interviews based on DSM-IV criteria.
The investigators expect to find significant reduction in social anxiety symptoms in all of the groups, with the cognitive behavior therapy group showing greater reduction in symptoms than the other groups. Mechanisms of change in all of the groups will be examined via measures of cognitive biases, affect, and other common and specific factors.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Attention Bias Modification (ABM)
Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
Attention Bias Modification (ABM)
Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
Cognitive Behavior Therapy
CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
Cognitive Behavior Therapy
CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Attention Bias Modification (ABM)
Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
Cognitive Behavior Therapy
CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* If on medication, patients must be on a stable dose
* Hebrew language fluency
Exclusion Criteria
* suicidal ideation
* Substance dependence within the past three months or current substance abuse
* Mental retardation or another pervasive developmental disability
* Current or past schizophrenia or psychosis, current bipolar disorder, or organic brain syndrome
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Israel Science Foundation
OTHER
Hebrew University of Jerusalem
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jonathan D. Huppert
Associate Professor, Department of Psychology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonathan D Huppert, PhD
Role: PRINCIPAL_INVESTIGATOR
Hebrew University of Jerusalem
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Hebrew University of Jerusalem
Jerusalem, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1624
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.